Product
burosumab
Aliases
Crysvita, KRN23, UX023
Name
CRYSVITA
INN Name
Burosumab
FDA Approved
Yes
4 clinical trials
1 organization
2 indications
1 document
Indication
X-linked hypophosphatemiaIndication
X-Linked HypophosphatemiaClinical trial
An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)Status: Completed, Estimated PCD: 2017-08-30
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)Status: Completed, Estimated PCD: 2016-12-22
Clinical trial
A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)Status: Completed, Estimated PCD: 2018-02-12
Clinical trial
A Randomized, Open-Label, Dose Finding, Phase 2 Study to Assess the Pharmacodynamics and Safety of the Anti-FGF23 Antibody, KRN23, in Pediatric Patients With X-linked Hypophosphatemia (XLH)Status: Completed, Estimated PCD: 2018-10-30
Document
DailyMed Label: CRYSVITAOrganization
Ultragenyx Pharmaceutical Inc.